Iomab-ACT (131-I apamistamab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Iomab-ACT (131-I apamistamab), covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma [EARLY_Phase 1]